Previous Close | 1,945.00 |
Open | 1,988.00 |
Bid | 1,944.00 x 20100 |
Ask | 1,945.00 x 1591600 |
Day's Range | 1,936.00 - 2,000.00 |
52 Week Range | 1,629.00 - 2,485.00 |
Volume | |
Avg. Volume | 1,891,110 |
Market Cap | 25.069B |
Beta (5Y Monthly) | 0.58 |
PE Ratio (TTM) | 10.68 |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | 0.70 (3.58%) |
Ex-Dividend Date | Mar 14, 2024 |
1y Target Est | N/A |
TEL AVIV, Israel, March 14, 2024--ICL (NYSE: ICL) (TASE: ICL), a leading global specialty minerals company, today announced the filing of its annual report on Form 20-F for the fiscal year ended December 31, 2023, with the U.S. Securities and Exchange Commission (SEC). Included, for the third year in a row, are Task Force on Climate-related Financial Disclosures (TCFD), which provide information on what ICL is doing to mitigate the risks of climate change and reduce its carbon footprint.
TEL AVIV, Israel, February 28, 2024--ICL (NYSE: ICL) (TASE: ICL), a leading global specialty minerals company, today announced it has acquired Nitro 1000, a manufacturer, developer and provider of biologicals in Brazil for approximately $30 million. This acquisition marks another meaningful step into the biologicals market, while expanding ICL’s product offerings and positioning the company for further expansions into new and adjacent end-markets.
TEL AVIV, Israel, February 28, 2024--ICL (NYSE: ICL) (TASE: ICL), a leading global specialty minerals company, today reported its financial results for the fourth quarter and full year ended December 31, 2023. Consolidated annual sales were $7,536 million versus a record $10,015 million in 2022. Net income was $647 million versus $2,159 million, while adjusted net income was $715 million versus $2,350 million. Annual adjusted EBITDA was $1,754 million versus $4,007 million in 2022. Diluted earni